Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W D Yu

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signalingR J Bernardi, D L Trump, W D Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2001
Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosisP A Hershberger, W D Yu, R A Modzelewski, et al.
Cancer Research|September 1, 1997
Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model systemB W Light, W D Yu, M C McElwain, et al.
Beijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences|August 21, 2018
[Cytotoxic effects of γδT cells on bladder cancer cells and expression of MICA/B in bladder cancer]J H Zhou, D Wang, H R Wang, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ miceC S Johnson, M J Chang, W D Yu, et al.
Journal of the National Cancer Institute|February 5, 1998
Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasoneW D Yu, M C McElwain, R A Modzelewski, et al.
Cancer Research|October 15, 1994
Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor modelM J Chang, W D Yu, L M Reyno, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signalingR J Bernardi, D L Trump, W D Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2001
Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosisP A Hershberger, W D Yu, R A Modzelewski, et al.
Cancer Research|September 1, 1997
Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model systemB W Light, W D Yu, M C McElwain, et al.
Beijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences|August 21, 2018
[Cytotoxic effects of γδT cells on bladder cancer cells and expression of MICA/B in bladder cancer]J H Zhou, D Wang, H R Wang, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ miceC S Johnson, M J Chang, W D Yu, et al.
Journal of the National Cancer Institute|February 5, 1998
Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasoneW D Yu, M C McElwain, R A Modzelewski, et al.
Cancer Research|October 15, 1994
Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor modelM J Chang, W D Yu, L M Reyno, et al.
Pageof 3